Release issued 21st October 2009

Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources

Patient-flow models will need to take into account that the highest percentage of patients take Lyrica
 
October 21, 2009-Waltham, Mass. - Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although the majority of surveyed U.S. physicians prescribe Eli Lilly's Cymbalta and Pfizer's Lyrica for the treatment of Fibromyalgia, neither agent has the majority of its uses in the first line. In the case of Cymbalta, surveyed rheumatologists report that 37 percent of their prescriptions for the drug are in the first line; in the case of Lyrica, 32 percent of prescriptions for the drug are in the first line.
 
"None of the Fibromyalgia agents we surveyed physicians about has the majority of its uses in the first line. Surveyed rheumatologists told us that similar percentages of their prescriptions for Amitriptyline and Cyclobenzaprine are in the first line compared with their prescriptions for Lyrica or Cymbalta, likely because Amitriptyline and Cyclobenzaprine have a long history of use in the treatment of Fibromyalgia (albeit off-label) and are available as inexpensive generics," stated Andrea Buurma, analyst at Decision Resources.
 
The new Treatment Algorithms in Fibromyalgia report also finds that Cymbalta is the agent most likely to lose patient share to Forest Laboratories/Cypress Bioscience's Savella by 2011. Savella was recently launched into the Fibromyalgia drug market in April 2009. However, Cymbalta is currently the only agent that is approved for both Fibromyalgia and depression and therefore it will continue to be surveyed physicians' drug of choice for Fibromyalgia patients with Comorbid Depression.
 
By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models. Patient-level claims data show that more patients turning to Cymbalta as a second-line or later therapy are prescribed the drug after Lyrica than vice versa. These data suggest that Cymbalta is positioned behind Lyrica; a likely scenario given Cymbalta was approved for Fibromyalgia one year following Lyrica's approval.
 
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread

(14th October 2009) Biosimilar Insulins and Insulin Analogues stand to erode US$6.1 billion in brand sales in the U.S. and Europe by 2018